Prometheus Stock
| Valuation | $41B |
| Valuation Date | Jun 11, 2026 |
| Implied Valuation | $42.39B |
| Last Price | $44.47 |
| 52-Week High | $44.47 |
| 52-Week Low | $19.00 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $18.8B1 |
| Latest Round Amount | $12B1 |
| Latest Round | Series B |
| Funding Rounds | 2 |
| IPO Status | n/a |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Prometheus
Prometheus (formerly Project Prometheus) is an artificial intelligence company focused on the development of AI tools that help engineers design and manufacture physical products. The company's "AI engineer" will assist in the creation of computers, spacecraft, jet engines, and other advanced machines.
Invest in Prometheus
Want to invest in Prometheus? Try our partner below.
Hiive is a marketplace for buying and selling shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
News
TSG Invest Adds Project Prometheus to Venture 50 as Cerebras Goes Public
HAUPPAUGE, N.Y., June 09, 2026 (GLOBE NEWSWIRE) -- TSG Invest, a multi-entity financial services firm providing accredited investors with research and access to pre-IPO opportunities, today announced ...
KBRA Assigns Preliminary Ratings to Sunrun Prometheus Issuer 2026-1, LLC
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to three classes of notes issued by Sunrun Prometheus Issuer 2026-1, LLC. The transaction is collateralized by a diver...
Elastic Adds Native Prometheus and PromQL Support to Elastic Observability
SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, today announced native Prometheus support, including direct ingestion via Remote Write and full PromQL support in Kibana. T...
Prometheus Energetics Breaks Ground on New Solid Rocket Motor Manufacturing Campus in Indiana
BLOOMFIELD, Ind. , Feb. 20, 2026 /PRNewswire/ -- Prometheus Energetics, LLC, a U.S.-based merchant supplier of solid rocket motors (SRMs) and energetics and a joint venture between Kratos Defense & Se...
Meta signs nuclear energy deals to power Prometheus AI supercluster
Meta said it has secured agreements with energy companies Vistra, TerraPower and Oklo, which are working on nuclear power technologies. They're planning to work together to eventually power Meta's Pro...
ENGIE Collaborates with Prometheus Hyperscale to Co-Develop Next-Generation AI-Ready Data Centers in Texas
HOUSTON , Sept. 2, 2025 /PRNewswire/ -- ENGIE North America (ENGIE) announced it has entered into an agreement with Prometheus Hyperscale ("Prometheus"), a leading sustainable hyperscale data center d...
Meta announces massive 'Prometheus' & 'Hyperion' data center plans
CNBC's Deirdre Bosa joins 'Money Movers' to discuss Big Tech's AI talent raid.
Prometheus Energetics to Establish an Approximate 550 Acre Solid Rocket Motor and Munitions Production Facility in Indiana as Part of DOD's Munitions Campus Pilot Program Led by the American Center for Manufacturing & Innovation
BLOOMFIELD, Ind., March 07, 2025 (GLOBE NEWSWIRE) -- The American Center for Manufacturing & Innovation (ACMI) and Prometheus Energetics (Prometheus), a U.S.-based merchant supplier of solid rocket mo...
Kratos & RAFAEL Establish Prometheus Energetics Joint Venture, a U.S.-Based Merchant Supplier of Solid Rocket Motors
SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, and RAFAEL Advanced De...
Lumen Partners with Prometheus Hyperscale to Enhance Connectivity for Sustainable AI-Driven Data Centers
Lumen ® Private Connectivity Fabric℠ will expand Prometheus' network capacity across its growing data center footprint DENVER , Dec. 17, 2024 /PRNewswire/ -- Prometheus Hyperscale has chosen Lumen Tec...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
WALTHAM, Mass. , Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering...
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatmen...
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
Merck Completes Acquisition of Prometheus Biosciences, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Completes Acquisition of Prometheus Biosciences, Inc.
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosc...
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosc...
Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus
Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.
Prometheus Biosciences stock soars amid $10.8 billion acquisition deal by Merck
Yahoo Finance Live highlights Prometheus Bioscience's stock performance amid the company's deal with pharmaceutical giant Merck.
Merck's $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunology
Merck & Co.'s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk o...
Biotech stock Prometheus Biosciences opened 70% up today: here's why
Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company for $10.8 billion.
Merck agrees to acquire Prometheus Biosciences
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.
Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish
Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.
Prometheus Biosciences, XPeng and State Street are among the stocks on the move
Here are some of the biggest movers on Monday:
Merck Offers to Buy Prometheus for $10.8 Billion
Merck & Co. Inc. has agreed to buy Prometheus Biosciences Inc. for about $10.8 billion. Su Keenan reports on Bloomberg Television.
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today anno...
Merck in Late-Stage Talks to Acquire Prometheus Biosciences
Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.
Yoshitsu Co., Ltd Welcomes Prometheus Capital Fund I, L.P. as a New Institutional Shareholder
Tokyo, Japan, April 14, 2023 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd (“Yoshitsu” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, as well as sundry pro...
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, developmen...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies –
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)
- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3 r d -
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development...
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development...
Prometheus Biosciences CEO on the company's ability to raise capital, get FDA approval
Cramer spoke with Prometheus Biosciences CEO Mark McKenna on Friday.
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development...
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development...
Prometheus shares rally 177% as it prepares to move drug into Phase 3 studies
Shares of Prometheus Biosciences Inc. RXDX, -4.40% soared 177.0% in premarket trading on Wednesday after the company said it will advance an experimental therapy into Phase 3 clinical trials for ulcer...
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p
THORNE HEALTHTECH'S ONEDRAW DEVICE USED IN DEPARTMENT OF DEFENSE'S CANCER MOONSHOT 2.0 PROJECT, PROMETHEUS, AS PART OF PRESIDENT BIDEN INITIATIVE
NEW YORK , Nov. 17, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and...
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 -
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF -
Prometheus Biosciences to Participate at September Healthcare Conferences
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development...
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 -
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
- G lobal Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn's disease patients -